Physician profile
Mariam Riad
NPI 1255891610
$3,930.23
in general payments reported to CMS, 2019-2025
11 companies · $3,634 in 2025
The $3,634 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $66.07 · 2024: $230 · 2025: $3,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,747 · Food and Beverage: $1,624 · Grant: $400 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,747.34 |
| Food and Beverage | $1,623.81 |
| Grant | $400.00 |
| Education | $159.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,391.65 | 2025 | Turbohawk, Hawkone |
| Abiomed | $634.77 | 2023-2025 | Impella |
| Boston Scientific Corporation | $483.73 | 2024-2025 | General - Catheter, General - Vascular Access |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Inspire Medical Systems, INC. | $132.41 | 2025 | Inspire |
| Stryker Corporation | $72.81 | 2025 | Artix Mt, Flowtriever, Clottriever Bold Catheter |
| Regeneron Healthcare Solutions, INC. | $17.68 | 2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $17.54 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals Lp | $17.37 | 2025 | Wainua |
| Amgen INC. | $17.13 | 2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2.14 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Riad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.